Target intelligence / Profile preview

Krüppel-like factor 2 (KLF2)

Target
KLF2
Molecular classification
Transcription factor, Zinc finger protein, Krüppel-like factor family
01

Overview

Krüppel-like factor 2 (KLF2) is a zinc finger transcription factor in the Krüppel-like factor family and plays a central role in the regulation of cell differentiation, quiescence, proliferation, adhesion, and migration across diverse cell types[1][3]. It was first described as lung Krüppel-like factor due to high expression in lung tissue, but it is also critical for vascular homeostasis, especially in endothelial cells, where it responds to laminar shear stress and is induced by drugs such as statins[2][3]. KLF2 is essential for normal embryonic development, notably vascular development, and regulates immune cell (B and T cell) differentiation, migration, and activation. Its loss contributes to diseases such as atherosclerosis, cardiovascular disease, and lymphoid malignancies like splenic marginal zone lymphoma and multiple myeloma[1][2][3]. KLF2 exerts anti-inflammatory and anti-thrombotic effects in endothelial cells, and its modulation is a mechanism of action for certain cardiovascular drugs such as statins[2].

Other names
Lung Krüppel-like factorLKLF
02

Mechanism of action

Induction of KLF2 enhances endothelial function, reduces pro-inflammatory gene expression, and induces anti-thrombotic pathways; therapeutic strategies may target KLF2 for vascular protection or regulation of immune cell function

03

Biological functions

Regulation of cell differentiationCell proliferationCell cycle arrest/quiescenceCell adhesionCell migrationRegulation of immune cell functionEndothelial homeostasisVascular development
04

Disease associations

Cardiovascular diseaseAtherosclerosisLymphoma (including splenic marginal zone lymphoma, multiple myeloma)InflammationOther (role in embryonic development, T and B cell-related immune diseases)
05

Safety considerations

Potential impact on vascular integrity and immune cell functioncomplete loss implicated in embryonic lethality and aberrant immune development
06

Interacting drugs

Statins (e.g., simvastatin, atorvastatin induce KLF2 expression)
07

Biomarkers

KLF2 expression levels in endothelial cells (for vascular health)KLF2 mutations in lymphoid malignancies (e.g., SMZL)KLF2 expression in multiple myeloma (potential prognostic marker)

Beyond the preview

Go deeper on Krüppel-like factor 2 (KLF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Krüppel-like factor 2 (KLF2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call